269 related articles for article (PubMed ID: 23369572)
1. Characterization of a dual-tropic human immunodeficiency virus (HIV-1) strain derived from the prototypical X4 isolate HXBc2.
Xiang SH; Pacheco B; Bowder D; Yuan W; Sodroski J
Virology; 2013 Mar; 438(1):5-13. PubMed ID: 23369572
[TBL] [Abstract][Full Text] [Related]
2. Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.
Cashin K; Roche M; Sterjovski J; Ellett A; Gray LR; Cunningham AL; Ramsland PA; Churchill MJ; Gorry PR
J Virol; 2011 Oct; 85(20):10699-709. PubMed ID: 21835796
[TBL] [Abstract][Full Text] [Related]
3. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
[TBL] [Abstract][Full Text] [Related]
4. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.
Polzer S; Dittmar MT; Schmitz H; Schreiber M
Virology; 2002 Dec; 304(1):70-80. PubMed ID: 12490404
[TBL] [Abstract][Full Text] [Related]
5. Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.
Dimonte S; Mercurio F; Svicher V; D'Arrigo R; Perno CF; Ceccherini-Silberstein F
Retrovirology; 2011 May; 8():33. PubMed ID: 21569409
[TBL] [Abstract][Full Text] [Related]
6. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma.
Soulié C; Tubiana R; Simon A; Lambert-Niclot S; Malet I; Canestri A; Brunet C; Murphy R; Katlama C; Calvez V; Marcelin AG
J Acquir Immune Defic Syndr; 2009 May; 51(1):60-4. PubMed ID: 19390328
[TBL] [Abstract][Full Text] [Related]
7. Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.
Del Prete GQ; Leslie GJ; Haggarty B; Jordan AP; Romano J; Hoxie JA
J Virol; 2010 Sep; 84(17):8777-89. PubMed ID: 20573813
[TBL] [Abstract][Full Text] [Related]
8. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.
Gray L; Roche M; Churchill MJ; Sterjovski J; Ellett A; Poumbourios P; Sherieff S; Wang B; Saksena N; Purcell DF; Wesselingh S; Cunningham AL; Brew BJ; Gabuzda D; Gorry PR
J Virol; 2009 Jun; 83(11):5430-41. PubMed ID: 19321618
[TBL] [Abstract][Full Text] [Related]
9. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
Kato K; Sato H; Takebe Y
J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
[TBL] [Abstract][Full Text] [Related]
10. Hybrid approach for predicting coreceptor used by HIV-1 from its V3 loop amino acid sequence.
Kumar R; Raghava GP
PLoS One; 2013; 8(4):e61437. PubMed ID: 23596523
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
[TBL] [Abstract][Full Text] [Related]
12. Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.
Cashin K; Jakobsen MR; Sterjovski J; Roche M; Ellett A; Flynn JK; Borm K; Gouillou M; Churchill MJ; Gorry PR
Retrovirology; 2013 Sep; 10():98. PubMed ID: 24041034
[TBL] [Abstract][Full Text] [Related]
13. X4-tropic human immunodeficiency virus IIIB utilizes CXCR4 as coreceptor, as distinct from R5X4-tropic viruses.
Islam S; Hoque SA; Adnan N; Tanaka A; Jinno-Oue A; Hoshino H
Microbiol Immunol; 2013 Jun; 57(6):437-44. PubMed ID: 23773022
[TBL] [Abstract][Full Text] [Related]
14. Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.
Nolan KM; Jordan AP; Hoxie JA
J Virol; 2008 Jan; 82(2):664-73. PubMed ID: 17977968
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
16. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
[TBL] [Abstract][Full Text] [Related]
17. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
[TBL] [Abstract][Full Text] [Related]
18. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.
Huang W; Eshleman SH; Toma J; Fransen S; Stawiski E; Paxinos EE; Whitcomb JM; Young AM; Donnell D; Mmiro F; Musoke P; Guay LA; Jackson JB; Parkin NT; Petropoulos CJ
J Virol; 2007 Aug; 81(15):7885-93. PubMed ID: 17507467
[TBL] [Abstract][Full Text] [Related]
19. Appraising the performance of genotyping tools in the prediction of coreceptor tropism in HIV-1 subtype C viruses.
Crous S; Shrestha RK; Travers SA
BMC Infect Dis; 2012 Sep; 12():203. PubMed ID: 22938574
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.
Nolan KM; Del Prete GQ; Jordan AP; Haggarty B; Romano J; Leslie GJ; Hoxie JA
J Virol; 2009 Apr; 83(8):3798-809. PubMed ID: 19193800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
